INTRODUCTION
Vitamin D deficiency is a common medical condition and an important focus of research. Vitamin D has been known for its role in regulation of calcium and bone development since many years ago. [1] Recently, the receptors of 1,25-dihydroxyvitamin D have been found on many cells, including immune cells. [2, 3] The expression of 1α hydroxylase (cyp27B1) activity in many of these cells supports [4] [5] [6] the idea that the Vitamin D has immunomodulating effects. Several genetic studies have of one prospective case-control study wer54e performed in Amsterdam [23] and did not support the association between low Vitamin D level and early stages of thyroid autoimmunity.
Most of the above-mentioned studies have a cross-sectional design, and to our best knowledge, no clinical trials have already been conducted on the effectiveness of Vitamin D treatment among Vitamin D deficient patients with AITDs.
Many of these studies have recommended that interventional clinical trials are necessary to determine the causal effect of Vitamin D deficiency in the pathogenesis of thyroid autoimmune diseases. Therefore, we designed this clinical trial to investigate the effect of Vitamin D deficiency treatment on thyroid function and autoimmunity marker, thyroid peroxidase antibody (TPO-Ab), in patients with Hashimoto's thyroiditis. The results of this study may be helpful to improve the management of AITDs and their prevention in susceptible people.
MATERIALS AND METHODS

Study design and participants
In this double-blind placebo-controlled randomized clinical trial which was conducted from February to July 2015 in Isfahan Endocrine and Metabolism Research Center (IEMRC), 120 hypothyroid or euthyroid adults with positive TPO-Ab were selected by consecutive sampling method. Hypothyroid patients were euthyroid and stable on levothyroxine at least for 6 months or had mild hypothyroidism on enrolment (thyroid-stimulating hormone [TSH] <15 mU/L). Serum Vitamin D levels of selected patients were measured. Those people with 25-hydroxyvitamin D (25[OH] D) ≤20 ng/mL were included in the study. Patients with renal or liver disease, cancer, pregnancy, severe weight loss, and those who were on immunosuppressive medication, insulin, sulfonamides, or any supplement were excluded from the study. Those patients who were on levothyroxine, metformin, or statin treatment enrolled if their medications had been started at least 6 months before enrolment, and no dose adjustment was done during the study period. [24] Study design explained for each person and participants knew that they may receive drug or placebo, and if they were in placebo group after completion of the study, their Vitamin D deficiency would be corrected by treatment. Each participant gave and signed a written informed consent. The research protocol was complied with the ethical standards of Helsinki Declaration (Edinburgh 2000) and approved by Regional Ethics Committee of Isfahan University of Medical Sciences.
The trial also was registered in the Iranian Registry of Clinical trials (IRCT) with the registration number IRCT2014120520216N1.
Procedures and variables assessment
Finally, 65 persons enrolled the study. Participants were randomly allocated using simple randomization to intervention (Vitamin D-treated) and control (placebo-treated) groups. Randomization was performed by a third person, and sealed drug boxes with label A or B were given to each person. Neither patients nor researchers knew the content of the boxes. After trial, the codes were broken. Patients in Vitamin D-treated group (n = 33) were assigned to receive pearls of Vitamin D, 50,000 unit weekly and those in control group (n = 32) were received placebo weekly for 12 weeks [ Figure 1 ]. Both Vitamin D and placebo pearls were provided and manufactured by Zahravi's pharmaceutical company, Tehran-Iran.
Demographic characteristics and medical history of all studied population were recorded. Physical examination was done by an expert endocrinologist. The blood pressure was measure by ERKA sphygmomanometer, weight and height by SECA stadiometer, and waist circumference by tape meter. Body mass index was calculated by dividing weight (kg) by square of height (m²).
At the beginning and at the end of the trial, two blood samples were taken from each person, one clot and one ethylenediaminetetraacetic acid containing blood sample. Biochemical tests including calcium (Ca), phosphorus (P), albumin, C-reactive protein (CRP), blood urea nitrogen, and creatinine (Cr) were measured on the day of sampling. However, the serum samples taken to measure TPO-Ab, TSH, 25(OH)D, and parathormone (PTH) froze and stored at −20°C to be analyzed at the same time with the second sample at the end of the trial.
Laboratory tests
All biochemical tests were done by photometric assays (BT 2000) using Pars kit (Tehran, Iran). TPO-Ab, PTH, and TSH were 
RESULTS
Three persons in Vitamin D-treated group and six persons in placebo-treated group were excluded or dropped. Finally, a total of 30 Vitamin D-treated and 26 placebo-treated participants attended the baseline examination and entered in statistical analysis [ Figure 1 ]. No one developed hypercalcemia during the study.
The clinical characteristics of the study participants are shown in Table 1 . Demographic, anthropometric, and laboratory data were not significantly different between Vitamin D-and placebo-treated groups at baseline (P > 0.05).
The concentrations of 25(OH)D, TSH, and TPO-Ab at baseline in vitamin D-and placebo-treated groups are presented in Table 1 Table 1 ].
The mean of the biochemical measurements including TPO-Ab, TSH, PTH, calcium, albumin, and creatinine in Vitamin D-and placebo-treated groups at baseline and after trial are presented in Table 2 .
Within-group comparison in Vitamin D-treated group, showed significant decrease for PTH (P = 0.001) but not for TSH, TPO-Ab, or other variables (P > 0.05). In placebo-treated group, there was not any significant changes in studied variables (P > 0.05).
Between-group analyses showed significant difference only in terms of mean PTH when adjustment was made for baseline values. No significant difference was observed between two study groups in none studied variables (P > 0.05).
DISCUSSION
We investigated the effect of Vitamin D treatment on autoimmune thyroid marker (TPO-Ab) and thyroid Kivity et al. in a cross-sectional study compared the level of Vitamin D in patients with AITDs, non-AITDs, and healthy people. They showed that the prevalence of Vitamin D deficiency was significantly higher in patients with AITDs than healthy persons. The rate of Vitamin D deficiency was also higher in patients with non-AITDs than healthy population. [25] Shin et al. in Korea studied the association between Vitamin D and TPO-Ab in patients with and without AITDs. They demonstrated that there was a significant negative correlation between Vitamin D level and TPO-Ab in patients with AITDs. [20] In a study in Turkey, Bozkurt et al. studied the relation between Vitamin D deficiency and Hashimoto's thyroiditis. They compared the level of Vitamin D and severity of Vitamin D deficiency between euthyroid patients with Hashimoto's thyroiditis and a healthy control group. Their results pointed out that there was correlation between severity of Vitamin D deficiency and thyroid volume, level of thyroid autoantibodies as well as duration of Hashimoto's thyroiditis. They concluded that Vitamin D may have potential role both in development and progression of Hashimoto's thyroiditis to hypothyroidism. [21] In a study in Tehran, Iran, Mansournia et al. reached to the similar conclusions. Furthermore, they showed that by 5 ng/mL increases in the level of Vitamin D, the risk of occurrence of Hashimoto's thyroiditis would be decreased by 19%. [26] Several other studies also reported similar results regarding the inverse association between Vitamin D level and AITDs. [26] [27] [28] [29] [30] On the other hand, some studies did not support the association between Vitamin D and thyroid autoimmunity. [23, [31] [32] [33] [34] Effraimidis et al. have conducted two case-control researches in the framework of Amsterdam AITD cohort study to determine the association between Vitamin D and early stages of thyroid autoimmunity. In one cross-sectional study, they compared the concentration of serum Vitamin D between euthyroid participants with genetic susceptibility for AITDs and negative thyroid antibodies and controls who were healthy women without family history of AITDs. In another longitudinal study, they compared level of Vitamin D between those euthyroid persons with genetic susceptibility for AITDs who developed TPO-Ab and those who did not. Their findings showed higher Vitamin D level in euthyroid participants with genetic susceptibility to AITDs than control group but not any significant differences between patients with newly diagnosed thyroid autoimmunity than control group. They concluded that Vitamin D is not correlate with early stages of thyroid autoimmunity. [23] D'Aurizio et al. did not find any association between low Vitamin D levels and AITDs , too. [31] The strength of our clinical trial was its novelty. This was the first randomized controlled clinical trial which evaluated the effects of Vitamin D treatment on thyroid autoimmune disease (Hashimoto's thyroiditis), in a prospective manner. We rely on 25(OH)D measurement to define Vitamin D deficiency (≤20 ng/mL) and assessing treatment efficacy with increasing the concentration of 25(OH)D to more than 30 ng/mL. We measured the baseline autoimmune marker and Vitamin D levels at the same time.
The limitations of this study were small sample size and short duration of follow-up period.
We recommend a larger sample size and longer follow-up and enrolment of people with positive family history of AITDs as they are more prone to AITDs and may benefit from potential prevention protocols.
CONCLUSION
The findings of this clinical trial did not support the hypothesis that Vitamin D treatment can improve thyroid autoimmune diseases.
